Overall, PD-L1 on immune cells may serve as a biomarker of an inflamed, T-cell-rich microenvironment primed for checkpoint blockade, whereas tumor-cell PD-L1 may denote adaptive immune resistance. Here, CD274 is linked to neoplasm.